Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 970–971 | Cite as

ASO Author Reflections: Fluorescent Anti-CEA IR800 for Tumor Labeling

  • Thinzar M. Lwin
  • Michael BouvetEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Lwin TM, Murakami T, Miyake K, Yazaki PJ, Hoffman RM, Bouvet M. Tumor-specific labeling of pancreatic cancer using a humanized anti-CEA antibody conjugated to a near-infrared fluorophore. Ann Surg Oncol 2018;25(4):1079–85.CrossRefGoogle Scholar
  2. 2.
    Boonstra MC, de Geus SWL, Prevoo HAJM, et al. Selecting targets for tumor imaging: an overview of cancer-associated membrane proteins. Biomark Cancer 2016;8:119–33.CrossRefGoogle Scholar
  3. 3.
    Lwin TM, Hoffman RM, Bouvet M. The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic. Expert Rev Anticancer Ther 2018;18(7):651–62.CrossRefGoogle Scholar
  4. 4.
    Moore LS, Rosenthal EL, de Boer E, et al. Effects of an unlabeled loading dose on tumor-specific uptake of a fluorescently labeled antibody for optical surgical navigation. Mol Imaging Biol 2017;19(4):610–6.CrossRefGoogle Scholar
  5. 5.
    Boogerd L, Vuijk FA, Hoogstins C, et al. Correlation between preoperative serum carcinoembryonic antigen levels and expression on pancreatic and rectal cancer tissue. Biomark Cancer 2017;9:1179299X17710016.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of California San DiegoSan DiegoUSA
  2. 2.VA San Diego Healthcare SystemSan DiegoUSA
  3. 3.Moores Cancer CenterUniversity of California San DiegoSan DiegoUSA

Personalised recommendations